Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study
Background: Sotrovimab is a neutralising monoclonal antibody (nMAB) currently available to treat extremely clinically vulnerable COVID-19 patients in England. Trials have shown it to have mild to moderate side effects, however, evidence regarding its safety in real-world settings remains insufficien...
| Үндсэн зохиолчид: | , , , , , |
|---|---|
| Формат: | Journal article |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Nature Research
2025
|